Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Should Turn Over AE Analysis Criteria To Firms – Boston Scientific Exec

This article was originally published in The Gray Sheet

Executive Summary

Much of the analysis of device-related adverse event reports currently handled by FDA could be completed by device manufacturers if the agency provided the criteria, according to Boston Scientific Manager for Quality and Regulatory Compliance Kristin Johnson

You may also be interested in...



Feigal, Tunis To Present At HHS Reg Reform Panel On FDA/CMS Partnerships

Collaborative opportunities between FDA and the Centers for Medicare & Medicare Services for approving new technologies will be explored during the upcoming 1HHS Advisory Committee on Regulatory Reform's public hearing in Minneapolis

CDRH To Start New Year By Expanding Alternative Summary Reporting

Malfunction reports for ventilators and surgical staplers will be eligible for alternative summary reporting (ASR) in early 2001, FDA Center for Devices and Radiological Health officials predict.

Sandoz Denosumab Biosimilar Progressing Faster Than Anticipated

Sandoz announced more than a year ago that its GP2411 biosimilar denosumab candidate had entered the clinic. Management provided an update on its progress at the recent Virtual Meet Novartis Management Investor Event.

UsernamePublicRestriction

Register

OM004559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel